Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
Thursday on WRAL at 6: Violence against healthcare workers is surging! WRAL Investigates why the people caring for us fear for their lives at work
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ptc Therapeutics
(NQ:
PTCT
)
43.35
+0.17 (+0.41%)
Streaming Delayed Price
Updated: 11:42 AM EST, Nov 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ptc Therapeutics
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 10, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 03, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
NASDAQ:PTCT Shareholder Notice: Investigation over Possible Securities Laws Violations by PTC Therapeutics, Inc.
October 10, 2023
San Diego, CA -- (SBWIRE) -- 10/10/2023 -- PTC Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
May 24, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
May 23, 2023
From
The Schall Law Firm
Via
Business Wire
Why did Sarepta Therapeutics Stock Plummet?
March 21, 2023
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Via
MarketBeat
Exposures
Product Safety
Newman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)
September 07, 2022
From
Newman Ferrara LLP
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm
June 16, 2022
From
The Schall Law Firm
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.